MRI Spectroscopy in Screening of Prostate Cancer
Background: The purpose of this study was to evaluate the suitability of MR Spectroscopy in screening for prostate cancer in comparison to T2-weighted MR imaging. Materials and Methods: Forty-six patients with biopsy confirmed prostate cancer underwent combined endorectal-body-phased-array MRI at 1....
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2007-01, Vol.27 (1B), p.687-693 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 693 |
|---|---|
| container_issue | 1B |
| container_start_page | 687 |
| container_title | Anticancer research |
| container_volume | 27 |
| creator | GOEB, Katja ENGEHAUSEN, Dirk G KRAUSE, F. Steffen HOLLENBACH, Hans-Peter NIEDOBITEK, Gerald BUETTNER, Maike FRANGOU, Phroso ENGELHARD, Karl |
| description | Background: The purpose of this study was to evaluate the suitability of MR Spectroscopy in screening for prostate cancer
in comparison to T2-weighted MR imaging. Materials and Methods: Forty-six patients with biopsy confirmed prostate cancer underwent
combined endorectal-body-phased-array MRI at 1.5T (Tesla). Twelve patients were additionally examined with 3D-spectroscopy
sequence. The results of the spectroscopy were compared with the findings of T2-weighted MR imaging and the histological examination
of radical prostatectomy specimens. Results: With 3D-spectroscopy, a choline+creatine/citrate-ratio of 0.45 for healthy tissue
and a ratio of 1.90 for tumor tissue were found and a significant difference between the groups was demonstrated. In 6 cases
diagnosis of tumor localization was improved with spectroscopy in comparison with T2-weighted imaging alone. Conclusion: 3D-spectroscopy
is a suitable technique for improving MR imaging of prostate cancer. This method can improve the diagnostic accuracy of T2-weighted
imaging alone. At present, 3D-CSI spectroscopy alone can not be recommended with sufficient validity. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70248174</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70248174</sourcerecordid><originalsourceid>FETCH-LOGICAL-h269t-7ee54aaa89bf9e0e09db9a98e81ce0d37d9fb2f32d32bbd1b33a07bbc63eb92c3</originalsourceid><addsrcrecordid>eNpFz0tLw0AUBeBBFFurf0Gy0V1gHsk8lhp8FCqK1fVwZ3LTRvJyJkX67w1Y6eoszseBc0LmTBmWqlzQUzKnPKepojSfkYsYvyiV0mhxTmZMiUxnks0JfXlfJusB_Rj66Pthn9RdsvYBsau7TdJXydtUjDBiUkDnMVySswqaiFeHXJDPx4eP4jldvT4ti7tVuuXSjKlCzDMA0MZVBilSUzoDRqNmHmkpVGkqxyvBS8GdK5kTAqhyzkuBznAvFuT2b3cI_fcO42jbOnpsGuiw30WrKM80U9kErw9w51os7RDqFsLe_n-cwM0BQPTQVGH6Ucej07nkXOij29ab7U8d0MYWmmaaFRYCV5bdW6mV-AVS7mfI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70248174</pqid></control><display><type>article</type><title>MRI Spectroscopy in Screening of Prostate Cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>GOEB, Katja ; ENGEHAUSEN, Dirk G ; KRAUSE, F. Steffen ; HOLLENBACH, Hans-Peter ; NIEDOBITEK, Gerald ; BUETTNER, Maike ; FRANGOU, Phroso ; ENGELHARD, Karl</creator><creatorcontrib>GOEB, Katja ; ENGEHAUSEN, Dirk G ; KRAUSE, F. Steffen ; HOLLENBACH, Hans-Peter ; NIEDOBITEK, Gerald ; BUETTNER, Maike ; FRANGOU, Phroso ; ENGELHARD, Karl</creatorcontrib><description>Background: The purpose of this study was to evaluate the suitability of MR Spectroscopy in screening for prostate cancer
in comparison to T2-weighted MR imaging. Materials and Methods: Forty-six patients with biopsy confirmed prostate cancer underwent
combined endorectal-body-phased-array MRI at 1.5T (Tesla). Twelve patients were additionally examined with 3D-spectroscopy
sequence. The results of the spectroscopy were compared with the findings of T2-weighted MR imaging and the histological examination
of radical prostatectomy specimens. Results: With 3D-spectroscopy, a choline+creatine/citrate-ratio of 0.45 for healthy tissue
and a ratio of 1.90 for tumor tissue were found and a significant difference between the groups was demonstrated. In 6 cases
diagnosis of tumor localization was improved with spectroscopy in comparison with T2-weighted imaging alone. Conclusion: 3D-spectroscopy
is a suitable technique for improving MR imaging of prostate cancer. This method can improve the diagnostic accuracy of T2-weighted
imaging alone. At present, 3D-CSI spectroscopy alone can not be recommended with sufficient validity.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 17348461</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Aged ; Biological and medical sciences ; Choline - analysis ; Citrates - analysis ; Creatine - analysis ; Humans ; Magnetic Resonance Imaging - methods ; Magnetic Resonance Spectroscopy - methods ; Male ; Mass Screening - methods ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - metabolism ; Reproducibility of Results ; Sensitivity and Specificity ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>Anticancer research, 2007-01, Vol.27 (1B), p.687-693</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18562238$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17348461$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GOEB, Katja</creatorcontrib><creatorcontrib>ENGEHAUSEN, Dirk G</creatorcontrib><creatorcontrib>KRAUSE, F. Steffen</creatorcontrib><creatorcontrib>HOLLENBACH, Hans-Peter</creatorcontrib><creatorcontrib>NIEDOBITEK, Gerald</creatorcontrib><creatorcontrib>BUETTNER, Maike</creatorcontrib><creatorcontrib>FRANGOU, Phroso</creatorcontrib><creatorcontrib>ENGELHARD, Karl</creatorcontrib><title>MRI Spectroscopy in Screening of Prostate Cancer</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Background: The purpose of this study was to evaluate the suitability of MR Spectroscopy in screening for prostate cancer
in comparison to T2-weighted MR imaging. Materials and Methods: Forty-six patients with biopsy confirmed prostate cancer underwent
combined endorectal-body-phased-array MRI at 1.5T (Tesla). Twelve patients were additionally examined with 3D-spectroscopy
sequence. The results of the spectroscopy were compared with the findings of T2-weighted MR imaging and the histological examination
of radical prostatectomy specimens. Results: With 3D-spectroscopy, a choline+creatine/citrate-ratio of 0.45 for healthy tissue
and a ratio of 1.90 for tumor tissue were found and a significant difference between the groups was demonstrated. In 6 cases
diagnosis of tumor localization was improved with spectroscopy in comparison with T2-weighted imaging alone. Conclusion: 3D-spectroscopy
is a suitable technique for improving MR imaging of prostate cancer. This method can improve the diagnostic accuracy of T2-weighted
imaging alone. At present, 3D-CSI spectroscopy alone can not be recommended with sufficient validity.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Choline - analysis</subject><subject>Citrates - analysis</subject><subject>Creatine - analysis</subject><subject>Humans</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Magnetic Resonance Spectroscopy - methods</subject><subject>Male</subject><subject>Mass Screening - methods</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFz0tLw0AUBeBBFFurf0Gy0V1gHsk8lhp8FCqK1fVwZ3LTRvJyJkX67w1Y6eoszseBc0LmTBmWqlzQUzKnPKepojSfkYsYvyiV0mhxTmZMiUxnks0JfXlfJusB_Rj66Pthn9RdsvYBsau7TdJXydtUjDBiUkDnMVySswqaiFeHXJDPx4eP4jldvT4ti7tVuuXSjKlCzDMA0MZVBilSUzoDRqNmHmkpVGkqxyvBS8GdK5kTAqhyzkuBznAvFuT2b3cI_fcO42jbOnpsGuiw30WrKM80U9kErw9w51os7RDqFsLe_n-cwM0BQPTQVGH6Ucej07nkXOij29ab7U8d0MYWmmaaFRYCV5bdW6mV-AVS7mfI</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>GOEB, Katja</creator><creator>ENGEHAUSEN, Dirk G</creator><creator>KRAUSE, F. Steffen</creator><creator>HOLLENBACH, Hans-Peter</creator><creator>NIEDOBITEK, Gerald</creator><creator>BUETTNER, Maike</creator><creator>FRANGOU, Phroso</creator><creator>ENGELHARD, Karl</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>MRI Spectroscopy in Screening of Prostate Cancer</title><author>GOEB, Katja ; ENGEHAUSEN, Dirk G ; KRAUSE, F. Steffen ; HOLLENBACH, Hans-Peter ; NIEDOBITEK, Gerald ; BUETTNER, Maike ; FRANGOU, Phroso ; ENGELHARD, Karl</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h269t-7ee54aaa89bf9e0e09db9a98e81ce0d37d9fb2f32d32bbd1b33a07bbc63eb92c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Choline - analysis</topic><topic>Citrates - analysis</topic><topic>Creatine - analysis</topic><topic>Humans</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Magnetic Resonance Spectroscopy - methods</topic><topic>Male</topic><topic>Mass Screening - methods</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GOEB, Katja</creatorcontrib><creatorcontrib>ENGEHAUSEN, Dirk G</creatorcontrib><creatorcontrib>KRAUSE, F. Steffen</creatorcontrib><creatorcontrib>HOLLENBACH, Hans-Peter</creatorcontrib><creatorcontrib>NIEDOBITEK, Gerald</creatorcontrib><creatorcontrib>BUETTNER, Maike</creatorcontrib><creatorcontrib>FRANGOU, Phroso</creatorcontrib><creatorcontrib>ENGELHARD, Karl</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GOEB, Katja</au><au>ENGEHAUSEN, Dirk G</au><au>KRAUSE, F. Steffen</au><au>HOLLENBACH, Hans-Peter</au><au>NIEDOBITEK, Gerald</au><au>BUETTNER, Maike</au><au>FRANGOU, Phroso</au><au>ENGELHARD, Karl</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MRI Spectroscopy in Screening of Prostate Cancer</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>27</volume><issue>1B</issue><spage>687</spage><epage>693</epage><pages>687-693</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Background: The purpose of this study was to evaluate the suitability of MR Spectroscopy in screening for prostate cancer
in comparison to T2-weighted MR imaging. Materials and Methods: Forty-six patients with biopsy confirmed prostate cancer underwent
combined endorectal-body-phased-array MRI at 1.5T (Tesla). Twelve patients were additionally examined with 3D-spectroscopy
sequence. The results of the spectroscopy were compared with the findings of T2-weighted MR imaging and the histological examination
of radical prostatectomy specimens. Results: With 3D-spectroscopy, a choline+creatine/citrate-ratio of 0.45 for healthy tissue
and a ratio of 1.90 for tumor tissue were found and a significant difference between the groups was demonstrated. In 6 cases
diagnosis of tumor localization was improved with spectroscopy in comparison with T2-weighted imaging alone. Conclusion: 3D-spectroscopy
is a suitable technique for improving MR imaging of prostate cancer. This method can improve the diagnostic accuracy of T2-weighted
imaging alone. At present, 3D-CSI spectroscopy alone can not be recommended with sufficient validity.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>17348461</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2007-01, Vol.27 (1B), p.687-693 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70248174 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Biological and medical sciences Choline - analysis Citrates - analysis Creatine - analysis Humans Magnetic Resonance Imaging - methods Magnetic Resonance Spectroscopy - methods Male Mass Screening - methods Medical sciences Middle Aged Nephrology. Urinary tract diseases Prostatic Neoplasms - diagnosis Prostatic Neoplasms - metabolism Reproducibility of Results Sensitivity and Specificity Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | MRI Spectroscopy in Screening of Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T15%3A48%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MRI%20Spectroscopy%20in%20Screening%20of%20Prostate%20Cancer&rft.jtitle=Anticancer%20research&rft.au=GOEB,%20Katja&rft.date=2007-01-01&rft.volume=27&rft.issue=1B&rft.spage=687&rft.epage=693&rft.pages=687-693&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E70248174%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70248174&rft_id=info:pmid/17348461&rfr_iscdi=true |